Skip to main content
    E

    Evaxion Biotech AS (EVAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.77
    +0.03 (+1.09%)

    Market Cap: $25.27M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Evaxion Biotech AS (EVAX) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Evaxion Biotech AS (EVAX) trades at 0.2x sales and 0.1x book value. Its P/B of 0.1x is below its 5-year median of 3.3x. Its forward P/E is 3.6x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E3.6x
    Price to sales0.2x
    Price to book0.1x
    EV/FCF0.4x
    PEGN/A
    FCF yield-1521.4%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B0.1x3.3xN/A
    Medians of month-end values through Oct 2026: 51 months (5-year).

    Valuation History

    Over the 3 of the 5 year ends shown that have a P/S, its P/S ranged from 0.7x in 2025 to 321.0x in 2023.

    Year endPriceP/SP/B
    2025$4.770.7x1.8x
    2024$4.231.8xN/A
    2023$34.29321.0xN/A
    2022$88.75N/A3.9x
    2021$221.00N/A3.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About EVAX

    What is EVAX's forward P/E ratio?

    Evaxion Biotech AS has a forward P/E ratio of 3.6x.

    What is EVAX's price to sales ratio?

    Evaxion Biotech AS has a price to sales ratio of 0.2x.